SG10202010386PA - Fused bicyclic compounds for the treatment of disease - Google Patents
Fused bicyclic compounds for the treatment of diseaseInfo
- Publication number
- SG10202010386PA SG10202010386PA SG10202010386PA SG10202010386PA SG10202010386PA SG 10202010386P A SG10202010386P A SG 10202010386PA SG 10202010386P A SG10202010386P A SG 10202010386PA SG 10202010386P A SG10202010386P A SG 10202010386PA SG 10202010386P A SG10202010386P A SG 10202010386PA
- Authority
- SG
- Singapore
- Prior art keywords
- disease
- treatment
- fused bicyclic
- bicyclic compounds
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462083031P | 2014-11-21 | 2014-11-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202010386PA true SG10202010386PA (en) | 2020-11-27 |
Family
ID=56014622
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202010386PA SG10202010386PA (en) | 2014-11-21 | 2015-11-20 | Fused bicyclic compounds for the treatment of disease |
| SG11201703953WA SG11201703953WA (en) | 2014-11-21 | 2015-11-20 | Fused bicyclic compounds for the treatment of disease |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201703953WA SG11201703953WA (en) | 2014-11-21 | 2015-11-20 | Fused bicyclic compounds for the treatment of disease |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US10233187B2 (en) |
| EP (1) | EP3221321B1 (en) |
| JP (3) | JP7224102B2 (en) |
| KR (1) | KR20170117020A (en) |
| CN (2) | CN107207513B (en) |
| AU (2) | AU2015349687B2 (en) |
| CA (1) | CA2968434A1 (en) |
| CL (1) | CL2017001289A1 (en) |
| CO (1) | CO2017005784A2 (en) |
| ES (1) | ES2911293T3 (en) |
| HK (1) | HK1244802A1 (en) |
| IL (1) | IL252309B (en) |
| MX (1) | MX370480B (en) |
| MY (1) | MY192927A (en) |
| RU (1) | RU2706007C2 (en) |
| SA (1) | SA517381566B1 (en) |
| SG (2) | SG10202010386PA (en) |
| WO (1) | WO2016081918A1 (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| MY194204A (en) | 2014-08-04 | 2022-11-21 | Nuevolution As | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
| SG10202010386PA (en) * | 2014-11-21 | 2020-11-27 | Akarna Therapeutics Ltd | Fused bicyclic compounds for the treatment of disease |
| EP3274350A1 (en) * | 2015-03-26 | 2018-01-31 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
| SG11201810290WA (en) * | 2016-05-25 | 2018-12-28 | Akarna Therapeutics Ltd | Combination therapies with farnesoid x receptor (fxr) modulators |
| EP3468962A1 (en) | 2016-06-13 | 2019-04-17 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
| CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
| PT4122464T (en) | 2017-03-28 | 2024-06-27 | Gilead Sciences Inc | Therapeutic combinations for treating liver diseases |
| CA3065313A1 (en) * | 2017-06-02 | 2018-12-06 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds |
| IL284591B1 (en) | 2019-01-15 | 2024-12-01 | Gilead Sciences Inc | FXR (NR1H4) Modulating Compounds |
| CN118388473A (en) | 2019-02-19 | 2024-07-26 | 吉利德科学公司 | Solid forms of FXR agonists |
| CN111825653A (en) * | 2019-04-19 | 2020-10-27 | 安道麦马克西姆有限公司 | Preparation of substituted pyrazoles and use thereof as anthranilamide precursors |
| AU2020319052A1 (en) | 2019-07-23 | 2022-01-27 | Novartis Ag | Combination treatment of liver diseases using FXR agonists |
| WO2021014349A1 (en) | 2019-07-23 | 2021-01-28 | Novartis Ag | Treatment comprising fxr agonists |
| JP2022547452A (en) | 2019-09-03 | 2022-11-14 | ノバルティス アーゲー | Treatment of liver disease or disorders, including ACTRII receptor antagonists |
| CN114401745A (en) | 2019-09-19 | 2022-04-26 | 诺华股份有限公司 | Treatments containing FXR agonists |
| EP4041233A1 (en) | 2019-09-30 | 2022-08-17 | Novartis AG | Treatment comprising the use of fxr agonists |
| CA3160522A1 (en) | 2019-12-20 | 2021-06-24 | Sanne Schroder Glad | Compounds active towards nuclear receptors |
| AU2020408067B2 (en) | 2019-12-20 | 2024-03-28 | Novartis Ag | Combination treatment of liver diseases using integrin inhibitors |
| EP4126874A1 (en) | 2020-03-31 | 2023-02-08 | Nuevolution A/S | Compounds active towards nuclear receptors |
| MX2022012259A (en) | 2020-03-31 | 2022-12-08 | Nuevolution As | Compounds active towards nuclear receptors. |
| TW202227405A (en) * | 2020-08-24 | 2022-07-16 | 以色列商安道麥馬克西姆有限公司 | Process for preparation of substituted pyrazoles |
| WO2022101853A1 (en) | 2020-11-16 | 2022-05-19 | Novartis Ag | Method of determining liver fibrosis |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7595311B2 (en) * | 2002-05-24 | 2009-09-29 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
| JP4679517B2 (en) * | 2003-07-23 | 2011-04-27 | エグゼリクシス， インコーポレイテッド | Azepine derivatives as drugs |
| US7402680B2 (en) | 2003-09-17 | 2008-07-22 | Janssen Pharmaceutica, N.V. | Fused heterocyclic compounds |
| US20090137554A1 (en) * | 2007-10-22 | 2009-05-28 | Wyeth | 1,4,5,6-TETRAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY |
| US20090215748A1 (en) * | 2007-12-20 | 2009-08-27 | Wyeth | FXR agonists for treating vitamin D associated diseases |
| CA2736880A1 (en) | 2008-09-26 | 2010-04-01 | Wyeth Llc | 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors |
| US8252826B2 (en) | 2010-03-24 | 2012-08-28 | Hoffmann-La Roche Inc. | Cyclopentyl- and cycloheptylpyrazoles |
| SG10202010386PA (en) * | 2014-11-21 | 2020-11-27 | Akarna Therapeutics Ltd | Fused bicyclic compounds for the treatment of disease |
| BR112018074231A2 (en) * | 2016-05-25 | 2019-03-06 | Akarna Therapeutics, Ltd. | fused bicyclic compounds for the treatment of disease |
-
2015
- 2015-11-20 SG SG10202010386PA patent/SG10202010386PA/en unknown
- 2015-11-20 MX MX2017006694A patent/MX370480B/en active IP Right Grant
- 2015-11-20 SG SG11201703953WA patent/SG11201703953WA/en unknown
- 2015-11-20 CN CN201580073351.8A patent/CN107207513B/en active Active
- 2015-11-20 ES ES15861717T patent/ES2911293T3/en active Active
- 2015-11-20 RU RU2017121588A patent/RU2706007C2/en active
- 2015-11-20 WO PCT/US2015/062017 patent/WO2016081918A1/en active Application Filing
- 2015-11-20 CN CN202010634386.7A patent/CN111662297A/en active Pending
- 2015-11-20 KR KR1020177016606A patent/KR20170117020A/en not_active Application Discontinuation
- 2015-11-20 MY MYPI2017701793A patent/MY192927A/en unknown
- 2015-11-20 EP EP15861717.5A patent/EP3221321B1/en active Active
- 2015-11-20 JP JP2017545870A patent/JP7224102B2/en active Active
- 2015-11-20 CA CA2968434A patent/CA2968434A1/en active Pending
- 2015-11-20 AU AU2015349687A patent/AU2015349687B2/en active Active
-
2017
- 2017-05-16 IL IL252309A patent/IL252309B/en active IP Right Grant
- 2017-05-19 US US15/599,647 patent/US10233187B2/en active Active
- 2017-05-19 CL CL2017001289A patent/CL2017001289A1/en unknown
- 2017-05-20 SA SA517381566A patent/SA517381566B1/en unknown
- 2017-06-12 CO CONC2017/0005784A patent/CO2017005784A2/en unknown
-
2018
- 2018-03-27 HK HK18104188.4A patent/HK1244802A1/en unknown
-
2019
- 2019-03-15 US US16/354,879 patent/US20190308977A1/en not_active Abandoned
-
2020
- 2020-07-22 JP JP2020125592A patent/JP2021011482A/en active Pending
- 2020-09-18 US US17/025,724 patent/US20210147426A1/en not_active Abandoned
- 2020-10-08 AU AU2020250270A patent/AU2020250270B2/en active Active
-
2022
- 2022-09-16 US US17/932,876 patent/US20230183247A1/en not_active Abandoned
- 2022-10-26 JP JP2022171339A patent/JP2023011731A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1244802A1 (en) | Fused bicyclic compounds for the treatment of disease | |
| HK1245795A1 (en) | Fused bicyclic compounds for the treatment of disease | |
| HK1244276A1 (en) | Fused pyrimidine compounds for the treatment of hiv | |
| HK1256795A1 (en) | Bipyrazolyl derivatives useful for the treatment of autoimmune diseases | |
| SMT201900172T1 (en) | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | |
| HRP20181672T1 (en) | Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers | |
| SI3210973T1 (en) | Heteroaryl compounds for the treatment of ophthalmic diseases | |
| HK1249756A1 (en) | Fused bicyclic compounds for the treatment of disease | |
| IL259297A (en) | Heterocyclic compounds for the treatment of disease | |
| IL250613A0 (en) | Substituted bicyclic compounds | |
| IL263177A (en) | Fused bicyclic compounds for the treatment of disease | |
| ZA201704589B (en) | Compounds for the treatment of cancer |